Biosynthesis of Self‐Assembled Proteinaceous Nanoparticles for Vaccination

Chao Pan,Jun Wu,Shuang Qing,Xiao Zhang,Lulu Zhang,Hua Yue,Ming Zeng,Bin Wang,Zheng Yuan,Yefeng Qiu,Huahu Ye,Dongshu Wang,Xiankai Liu,Peng Sun,Bo Liu,Erling Feng,Xiaoyong Gao,Li Zhu,Wei Wei,Guanghui Ma,Hengliang Wang

DOI: https://doi.org/10.1002/adma.202002940

IF: 29.4

2020-09-02

Advanced Materials

Abstract:<p>Recent years have seen enormous advances in nanovaccines for both prophylactic and therapeutic applications, but most of these technologies employ chemical or hybrid semi‐biosynthetic production methods. Thus, production of nanovaccines has to date failed to exploit biology‐only processes like complex sequential post‐translational biochemical modifications and scalability, limiting the realization of the initial promise for offering major performance advantages and improved therapeutic outcomes over conventional vaccines. A Nano‐B5 platform for in vivo production of fully protein‐based, self‐assembling, stable nanovaccines bearing diverse antigens including peptides and polysaccharides is presented here. Combined with the self‐assembly capacities of pentamer domains from the bacterial AB₅ toxin and unnatural trimer peptides, diverse nanovaccine structures can be produced in common <i>Escherichia coli</i> strains and in attenuated pathogenic strains. Notably, the chassis of these nanovaccines functions as an immunostimulant. After showing excellent lymph node targeting and immunoresponse elicitation and safety performance in both mouse and monkey models, the strong prophylactic effects of these nanovaccines against infection, as well as their efficient therapeutic effects against tumors are further demonstrated. Thus, the Nano‐B5 platform can efficiently combine diverse modular components and antigen cargos to efficiently generate a potentially very large diversity of nanovaccine structures using many bacterial species.</p>

materials science, multidisciplinary,chemistry, physical,physics, applied, condensed matter,nanoscience & nanotechnology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a method completely based on biological processes in vaccinology to produce nano - vaccines. Specifically, the paper proposes a platform named Nano - B5 for in - vivo production of fully protein - based, self - assembling, and stable nano - vaccines that can carry multiple antigens, including peptides and polysaccharides. This platform aims to overcome the limitations in existing nano - vaccine technologies, such as the limitations of chemical or semi - biosynthetic methods in antigen diversity and biocompatibility. By combining the self - assembling ability formed by the B5 subunit of bacterial AB5 toxin and non - natural tripeptides, the Nano - B5 platform can produce nano - vaccine structures with high diversity in common Escherichia coli strains and attenuated pathogen strains. In addition, this platform also demonstrates its excellent performance in lymph node targeting, immune response activation, and safety, and proves its powerful effects in preventing infections and treating tumors. Therefore, the Nano - B5 platform provides an attractive technological platform for combining diverse self - adjuvant modular chassis components and antigen cargos to generate various high - performance nano - vaccines.